I am a Healthcare Professional outside the US and UK

I am a Healthcare Professional outside the US and UK

Click here for international medical scientific information about Oncology for Healthcare Professionals.

I am not a Healthcare Professional and I am outside the US and the UK

I am not a Healthcare Professional and I am outside the US and the UK

Click here for general international information for patients, caregivers and the general public.

Country-specific medical scientific information

Country-specific medical scientific information

Country-specific medical scientific information for Healthcare Professionals.

This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

InOncology.com

ASCO 2019 - Grohe poster

Nintedanib plus docetaxel in lung adenocarcinoma patients following treatment with immune checkpoint inhibitors: preliminary efficacy and safety results of the non-interventional study VARGADO

Grohé C, Blau W, Gleiber W, Haas S, Müller-Huesmann H, Schulze M, Atz J, Kaiser R

RELATED ARTICLES

Learn more about the science behind this presentation in the papers and other materials below

Efficacy of nintedanib and docetaxel in patients with advanced lung adenocarcinoma treated with first-line chemotherapy and second-line immunotherapy in the nintedanib NPU program

Corral J et al. CTO 2019; DOI: 10.1007/s12094-019-02053-7

Efficacy and safety of nintedanib and docetaxel in lung adenocarcinoma patients following treatment with immune checkpoint inhibitors: first interim results of the ongoing non-interventional VARGADO study (NCT02392455)

Grohé C et al. Poster presented at ESMO I-O 2018 (Poster 55P)

Nintedanib is being investigated in malignant pleural mesothelioma (MPM) and is not approved for this use. The efficacy and safety of nintedanib in MPM have not been established.

Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. For the full list of country-specific information please click here. Nintedanib is not approved in other oncology indications.

© 2019 Boehringer Ingelheim International GmbH. All rights reserved.

Page last updated: May 2019